New Guidelines and Novel Treatments for PAH: Taking a Forward-Looking Data Dive Into the Pool of Emerging Therapies
Released On
June 21, 2024
Expires On
June 21, 2025
Media Type
Internet
Completion Time
60 minutes
Specialty
Acute Care, Cardiology, Critical Care, Hospitalist, Pulmonology
Topic(s)
Acute Heart Failure, Cardiovascular Disease, Heart, Heart Disease
This activity is provided by Integrity CE, LLC.
This activity is supported by an educational grant from Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson
Credit Available
- Physicians — maximum of 1.0 AMA PRA Category 1 Credit™
All other healthcare professionals completing this course will be issued a statement of participation.
Target Audience
This educational activity has been designed to meet the needs of cardiologists, pulmonologists, rheumatologists, and other physicians, including those in primary care and internal medicine, as well as physician assistants, nurse practitioners, and other healthcare providers who may be involved in managing care for patients with pulmonary arterial hypertension (PAH).
Program Overview
Discoveries about the pathogenesis of pulmonary arterial hypertension (PAH) revealed key molecular pathways that could be targeted to treat this cardiopulmonary disorder. A multitude of new therapies with differing mechanisms of action began to appear in the late 1990s and experts discovered that combination treatments were key to extending life. Today, 5-year survival rates approach 70%.
Premiere clinical guidelines on diagnosing and managing PAH were recently revised and updated and in March 2024, two new treatment choices were approved by the FDA — a fixed-dose, single-tablet combination of the two drug classes that are recommended as initial treatment for most patients, and a first-in-class transforming growth factor inhibitor.
Join PAH expert Dr. John J. Ryan for this on-demand data dive activity that explores recent guideline changes, newly approved treatments, and freshly released data on emerging therapies.
Learning Objectives
Upon completion of this educational activity, participants should be able to:
- Assess new and revised recommendations for the management of PAH outlined in the 2022 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension
- Integrate investigational treatments (when available) into PAH treatment selections based on recently released or forthcoming clinical trial findings
Faculty
John J. Ryan, MD, MB, BCh, BAO
Professor, University of Utah
Director, Pulmonary Hypertension Comprehensive Care Center
Director, Cardiovascular Medicine Fellowship Program
Interim Chief of General Cardiology
University of Utah Hospital
University of Utah School of Medicine
Salt Lake City, Utah
Physician Accreditation Statement
Integrity CE, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physician Credit Designation
Integrity CE, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures of Relevant Financial Relationship(s)
Integrity CE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity CE, LLC for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.
The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CME activities:
- John J. Ryan, MD, MB, BCh, BAO
- Advisor, researcher, speaker for: Johnson and Johnson, Kiniksa Pharmaceuticals, Merck, United Therapeutics
The Integrity CE, LLC planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.
Instructions for Participation and Credit
There are no fees for participating and receiving CME credit for this activity. During the period June 21, 2024 through June 21, 2025, participants must:
- Read the learning objectives
- Complete the pretest
- Study the educational activity
- Complete the posttest and the evaluation form
A statement of credit will be issued only upon receipt of a completed posttest with a score of 75% or better and a completed activity evaluation form.
Course Viewing Requirements
Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Browsers:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity CE, LLC does not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.
Contact Information
For information about ACCME accreditation of this activity, please contact Integrity CE LLC, at (855) 835-4004 or [email protected].